A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
for Geographic Atrophy Secondary to Age-related Macular Degeneration
78 locations incl. Gilbert
Sponsor: Apellis Pharmaceuticals, Inc.
Sex: All·Age: 60+
Code: NCT07215390·Phase 2·Recruiting·Listed Oct 2025